Results 31 to 40 of about 7,402 (202)

El reto del envejecimiento y la complejidad farmacoterapéutica en el paciente VIH+ [PDF]

, 2018
Objective: To describe the current knowledge and management of aging and pharmacotherapeutic complexity in HIV + patients. Method: A review of literature was carried out, including articles, originals or reviews, published in English or Spanish, from ...
Abdel Kader Martín, Laila, Morillo Verdugo, Ramón A., Ramos Blanco, José Ramón, Álvarez de Sotomayor Paz, María   +3 more
core   +3 more sources

Endothelial Glycocalyx Integrity in Treatment-Naïve People Living with HIV before and One Year after Antiretroviral Treatment Initiation

Viruses, 2023
Endothelial glycocalyx (EG) derangement has been associated with cardiovascular disease (CVD). Studies on EG integrity among people living with HIV (PLWH), are lacking.
Paraskevi C. Fragkou, Ignatios Ikonomidis, Dimitrios Benas, Dimitra Kavatha, Charalampos D. Moschopoulos, Konstantinos Protopapas, Gavriella Kostelli, John Thymis, Dionysia Mpirmpa, Irene Galani, Maria Tsakona, Chrysanthi Oikonomopoulou, George Theocharous, Vassilis G. Gorgoulis, Parisis Gallos, Sotirios Tsiodras, Anastasia Antoniadou, Antonios Papadopoulos, Helen Triantafyllidi   +18 more
doaj   +1 more source

Data on the stability of darunavir/cobicistat suspension after tablet manipulation

Data in Brief, 2020
The COVID-19 outbreak is now one of the most critical crises to manage for most of the national healthcare systems in the world. In the absence of authorised pharmacological treatments, many antiretrovirals, including darunavir/cobicistat fixed ...
D. Zanon, A. Manca, A. De Nicolò, A. D'Avolio, U.M. Musazzi, F. Cilurzo, N. Maximova, C. Tomasello, P. Minghetti   +8 more
doaj   +1 more source

Stability-indicating method development and validation for the concurrent determination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide by UPLC in bulk and tablet dosage forms

Future Journal of Pharmaceutical Sciences, 2021
Background Tablet dosage forms containing combination of darunavir a protease inhibitor, cobicistat a cytochrome P450 3A inhibitor, emtricitabine and tenofovir alafenamide which were nucleoside reverse transcriptase inhibitors were approved by USFDA on ...
M. Satya Venkata Sakuntala, A. Lakshmana Rao, M. William Carey   +2 more
doaj   +1 more source

Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients

Microbiology Spectrum, 2023
Data regarding the durability of tenofovir alafenamide (TAF)-containing antiretroviral therapy (ART) in maintaining hepatitis B virus (HBV) viral suppression among HIV/HBV-coinfected patients are limited.
Yu-Shan Huang, Chien-Yu Cheng, Hsin-Yun Sun, Shu-Hsing Cheng, Po-Liang Lu, Chen-Hsiang Lee, Yuan-Ti Lee, Hung-Chin Tsai, Chia-Jui Yang, Chun-Eng Liu, Bo-Huang Liou, Shih-Ping Lin, Sung-Hsi Huang, Mao-Wang Ho, Hung-Jen Tang, Chien-Ching Hung   +15 more
doaj   +1 more source

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study [PDF]

, 2016
BACKGROUND: Tenofovir alafenamide (TAF) is a novel tenofovir prodrug with improved renal and bone safety compared with TDF-containing regimens. We report the 48 week safety and efficacy of a once-daily single tablet regimen of elvitegravir 150 mg (E ...
Abram, Michael E., Arribas, Jose R., Avihingsanon, Anchalee, Benson, Paul, Bloch, Mark, Cheng, Andrew, Chetchotisakd, Ploenchan, Crofoot, Gordon, Custodio, Joseph M., Fordyce, Marshall W., Gathe, Joseph, Gupta, Samir K., Lichtenstein, Kenneth, McCallister, Scott, Post, Frank A., Pozniak, Anton, Ramgopal, Moti, SenGupta, Devi, Wei, Xuelian   +18 more
core   +1 more source

Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials

Journal of Microbiology, Immunology and Infection, 2021
Despite aggressive efforts on containment measures for the coronavirus disease 2019 (COVID-19) pandemic around the world, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously spreading.
Chih-Cheng Lai, Chien-Ming Chao, Po-Ren Hsueh   +2 more
doaj   +1 more source

Pharmacokinetics (PK) of ethinylestradiol/levonorgestrel co-administered with atazanavir/cobicistat

HIV Research & Clinical Practice, 2019
Background and objectives: Access to safe and reliable contraception in the context of ARVs is essential. This study aimed to investigate the steady-state pharmacokinetics (PK) of ethinylestradiol/levonorgestrel (EE/LNG) 30/150 μg (Microgynon®) and ...
Emilie R Elliot, Elisa Bisdomini, Sujan Dilly Penchala, Saye Khoo, Nneka Nwokolo, Marta Boffito   +5 more
doaj   +1 more source

The effect of ivermectin alone and in combination with cobicistat or elacridar in experimental Schistosoma mansoni infection in mice

Scientific Reports, 2021
Schistosoma mansoni is less susceptible to the antiparasitic drug ivermectin than other helminths. By inhibiting the P-glycoprotein or cytochrome P450 3A in mice host or parasites in a murine model, we aimed at increasing the sensitivity of S. mansoni to
Belén Vicente, Julio López-Abán, Juliane Chaccour, Juan Hernández-Goenaga, Patricia Nicolas, Pedro Fernández-Soto, Antonio Muro, Carlos Chaccour   +7 more
doaj   +1 more source

Week 48 resistance analyses of the once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials [PDF]

, 2019
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed ...
Ajana, F, Antela, A, Antinori, A, Arasteh, K, Arribas, JR, Baugh, Bryan, Belonosova, E, Benson, P, Berenguer, J, Bhatti, L, Bickel, M, Bogner, J, Bredeek, F, Brown, Kimberley, Brunetta, J, Casado, J, Castelli, F, Chernova, O, Chirianni, A, Clarke, A, Conway, B, Cotte, L, Crofoot, G, Cunningham, D, De Los Santos, I, De Luca, A, De Meyer, Sandra, De Wit, S, DeJesus, E, deVente, J, Di Biagio, A, Dushkina, N, Eron, J, Esser, S, Estrada, V, Faetkenheuer, G, Felizarta, F, Florence, E, Franco, R, Galindo, MJ, Gallant, J, Galli, M, Garcia Del Toro, M, Garlicki, A, Gasiorowski, J, Gatell, JM, Gazzard, BG, Ghys, Anne, Girard, P-M, Gorgolas, M, Gutierrez, F, Gutierrez, MDM, Hagins, D, Halota, W, Henry, K, Horban, A, Jayaweera, D, Jessen, H, Jezorwski, John, Johnson, MA, Katlama, C, Kern, W, Klein, M, Kulagin, V, Lathouwers, Erkki, Lazzarin, A, Lucasti, C, Maggiolo, F, Martorell, C, Maserati, R, McDonald, C, McGowan, J, Mills, A, Mohsine, El Ghazi, Molina, J-M, Morales-Ramirez, J, Moutschen, M, Murphy, D, Mussini, C, Negredo, E, Opsomer, Magda, Orkin, C, Parczewski, M, Piekarska, A, Pineda, JA, Podzamczer, D, Poizot-Martin, I, Portilla Sogorb, J, Prelutsky, D, Rachlis, A, Raffi, F, Ramgopal, M, Rashbaum, B, Reeves, I, Rey, D, Reynes, J, Rivero, A, Rockstroh, J, Ruane, P, Rubio, R, Ryamova, E, Shafran, S, Shuldyakov, A, Sizova, N, Slim, J, Spinner, C, Stellbrink, H-J, Stoehr, A, Teicher, E, Tsybakova, O, Van Landuyt, Erika, Van Wijngaerden, E, Vandekerckhove, L, Vandercam, B, Vekerckhove, L, Vercam, B, Viciana, P, Voronin, E, Walmsley, S, Waters, L, Wilkin, A, Wong, Eric Y, Yakovlev, A, Yazdanpanah, Y   +123 more
core   +3 more sources